Mamata Chand
Rheumatology · Fairfax, VANPI 1275947467
Payments from drug & device makers
Across 510 payments — averaging $21.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$2K
- AbbVie$2K
- UCB, Inc.$1K
- Johnson & Johnson$1K
- Novartis$875
- ANI Pharmaceuticals, Inc.$743
- plus $4K from 25 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 86 | $1,966 |
| AbbVie | 85 | $1,667 |
| UCB, Inc. | 61 | $1,086 |
| Johnson & Johnson | 42 | $1,025 |
| Novartis | 39 | $875 |
| ANI Pharmaceuticals, Inc. | 43 | $743 |
| AstraZeneca(2 entities) | 22 | $536 |
| GSK | 23 | $412 |
| Pfizer | 13 | $296 |
| Fresenius Kabi USA, LLC | 17 | $290 |
| Lilly USA, LLC | 12 | $276 |
| E.r. Squibb & Sons, L.L.C. | 9 | $223 |
| Aurinia Pharma U.S., Inc. | 8 | $206 |
| Radius Health, Inc. | 7 | $160 |
| Sanofi | 7 | $156 |
| Mallinckrodt Hospital Products Inc. | 5 | $152 |
| Cumberland Pharmaceuticals, Inc. | 1 | $145 |
| Genentech USA, Inc. | 5 | $122 |
| Tersera Therapeutics LLC | 6 | $114 |
| Sandoz | 5 | $106 |
| Pharming Healthcare, Inc. | 3 | $64 |
| Organon | 2 | $48 |
| Mylan Institutional Inc. | 1 | $31 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $29 |
| Boehringer Ingelheim | 1 | $28 |
| Scilex Pharmaceuticals Inc. | 1 | $25 |
| Tonix Medicines, Inc. | 1 | $22 |
| Bioventus LLC | 1 | $20 |
| Kyowa Kirin, Inc. | 1 | $18 |
| Sobi, Inc | 1 | $16 |
| Merck | 1 | $16 |
How this compares
$10,873 in reported general payments places this provider in the 70th percentile of 159 rheumatology providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other rheumatology in Fairfax
- Peter LipskyCharlottesville$1.6M
- Sharukh ShroffDanville$1.5M
- Kristi MizelleNewport News$1.2M
- Phillip KempfArlington$467K
- Adegbenga BankoleRoanoke$355K
- Michael StrachanRichmond$158K
- Karim MasriRichmond$147K
- Michael CannonVirginia Beach$145K
- Phong NguyenReston$127K
- Roger LidmanChesapeake$118K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.